Exploiting oxidative phosphorylation to promote the stem and immunoevasive properties of pancreatic cancer stem cells.
Sandra ValleSonia AlcaláLaura Martin-HijanoPablo Cabezas-SainzDiego NavarroEdurne Ramos MuñozLourdes YusteKanishka TiwaryKarolin WalterLaura Ruiz-CañasMarta Alonso-NoceloJuan Andrés RubioloEmilio González-ArnayChristopher HeeschenLaura Garcia-BermejoPatrick C HermannLaura E SánchezPatricia SanchoMiguel Ángel Fernández-MorenoBruno SainzPublished in: Nature communications (2020)
Pancreatic ductal adenocarcinoma (PDAC), the fourth leading cause of cancer death, has a 5-year survival rate of approximately 7-9%. The ineffectiveness of anti-PDAC therapies is believed to be due to the existence of a subpopulation of tumor cells known as cancer stem cells (CSCs), which are functionally plastic, and have exclusive tumorigenic, chemoresistant and metastatic capacities. Herein, we describe a 2D in vitro system for long-term enrichment of pancreatic CSCs that is amenable to biological and CSC-specific studies. By changing the carbon source from glucose to galactose in vitro, we force PDAC cells to utilize OXPHOS, resulting in enrichment of CSCs defined by increased CSC biomarker and pluripotency gene expression, greater tumorigenic potential, induced but reversible quiescence, increased OXPHOS activity, enhanced invasiveness, and upregulated immune evasion properties. This CSC enrichment method can facilitate the discovery of new CSC-specific hallmarks for future development into targets for PDAC-based therapies.
Keyphrases
- cancer stem cells
- gene expression
- induced apoptosis
- papillary thyroid
- squamous cell carcinoma
- small cell lung cancer
- cell cycle arrest
- dna methylation
- high glucose
- diabetic rats
- squamous cell
- oxidative stress
- cell death
- high throughput
- drug induced
- blood glucose
- signaling pathway
- risk assessment
- young adults
- protein kinase
- metabolic syndrome
- insulin resistance
- cell fate
- human health
- embryonic stem cells
- pi k akt
- glycemic control